Comparing Ethema Health (OTCMKTS:GRST) & Bausch + Lomb (NYSE:BLCO)

Ethema Health (OTCMKTS:GRST) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Volatility & Risk

Ethema Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ethema Health and Bausch + Lomb”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ethema Health	$6.02 million	0.13	-$2.06 million	N/A	N/A
Bausch + Lomb	$5.10 billion	1.12	-$360.00 million	($0.62)	-25.73

Ethema Health has higher earnings, but lower revenue than Bausch + Lomb.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ethema Health and Bausch + Lomb, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ethema Health	0	0	0	0	0.00
Bausch + Lomb	1	9	4	0	2.21

Bausch + Lomb has a consensus target price of $18.08, suggesting a potential upside of 13.37%. Given Bausch + Lomb’s stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Ethema Health.

Profitability

This table compares Ethema Health and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ethema Health	-9.35%	N/A	-5.77%
Bausch + Lomb	-4.21%	3.60%	1.69%

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. 55.8% of Ethema Health shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bausch + Lomb beats Ethema Health on 9 of the 12 factors compared between the two stocks.

About Ethema Health

Ethema Health Corporation operates behavioral healthcare space specifically in the treatment of substance use disorders. It offers rehabilitation services. The company was formerly known as GreeneStone Healthcare Corporation and changed its name to Ethema Health Corporation in April 2017. Ethema Health Corporation is based in West Palm Beach, Florida.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.